Ahead of Dextenza’s planned mid-2019 U.S. launch for post-cataract pain, Ocular Therapeutix is expected to report data from both OTX-TP and OTX-TIC in glaucoma are expected in first half of 2019, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Now funded into 2020, Ocular shares remain undervalued for its suite of hydrogel-based products for both the front and back of the eye, Catanzaro contends. He maintains an Overweight rating on the shares with a $14 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.